Recurrent Primitive Neuroectodermal Tumor: Clinical Trials

1 completed, 1 unknown. 2 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	2	Completed 1, Unknown 1
Phase 1	1	Unknown 1

Follow Recurrent Primitive Neuroectodermal Tumor: new trials by email Literature Review of Recurrent Primitive Neuroectodermal Tumor trials Research Report on Recurrent Primitive Neuroectodermal Tumor

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma	Phase 2	Completed	National Cancer Institute (NCI)	108	2010-11-22	2021-07-23
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors Carboplatin, Mannitol, Melphalan - Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered	Phase 1 / Phase 2	Unknown	OHSU Knight Cancer Institute	17	2009-07-09	2021-10-26

Narrower conditions

Medulloblastoma (2)  ·  Neuroectodermal Tumors, Primitive (2)  ·  Central Nervous System Neoplasms (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neuroectodermal Tumors, Primitive, Peripheral (1)  ·  Pinealoma (1)

Broader conditions

Glioma (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Neoplasms, Neuroepithelial (2)  ·  Neuroectodermal Tumors (2)  ·  Brain Diseases (1)  ·  Brain Neoplasms (1)  ·  Central Nervous System Diseases (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Nervous System Diseases (1)  ·  Nervous System Neoplasms (1)

Interventions

Bevacizumab (1)  ·  Carboplatin (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Irinotecan (1)  ·  Mannitol (1)  ·  Melphalan (1)  ·  Temozolomide (1)  ·  sodium thiosulfate (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)

Countries

United States (2)  ·  Australia (1)  ·  Canada (1)  ·  New Zealand (1)  ·  Puerto Rico (1)

Top investigators

Adam S Levy (1)  ·  Edward A Neuwelt (1)

NIH funding

R01NS044687 (1), U10CA098543 (1), U10CA180886 (1)